Metformin use and risk of ischemic stroke in patients with type 2 diabetes: A cohort study.
- Author:
Huan YU
1
,
2
;
Ruo Tong YANG
1
,
2
;
Si Yue WANG
1
,
2
;
Jun Hui WU
1
,
2
;
Meng Ying WANG
1
,
2
;
Xue ying QIN
1
,
2
;
Tao WU
1
,
2
;
Da Fang CHEN
1
,
2
;
Yi Qun WU
1
,
2
;
Yong Hua HU
1
,
2
Author Information
1. Department of Epidemiology and Biostatistics, Peking University School of Public Health
2. Key Laboratory of Epidemiology of Major Diseases (Peking University), Ministry of Education, Beijing 100191, China.
- Publication Type:Journal Article
- Keywords:
Cohort study;
Ischemic stroke;
Metformin;
Type 2 diabetes
- MeSH:
Humans;
Male;
Middle Aged;
Aged;
Female;
Metformin/adverse effects*;
Diabetes Mellitus, Type 2/drug therapy*;
Cohort Studies;
Ischemic Stroke/complications*;
Prospective Studies;
Hypoglycemic Agents/adverse effects*;
Stroke/prevention & control*;
Retrospective Studies
- From:
Journal of Peking University(Health Sciences)
2023;55(3):456-464
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the association between the use of metformin and the risk of ischemic stroke in patients with type 2 diabetes.
METHODS:A prospective cohort study was designed from the Fangshan family cohort in Beijing. According to metformin use at baseline, 2 625 patients with type 2 diabetes in Fangshan, Beijing were divided into metformin group or non-metformin group and the incidence of ischemic stroke between the different groups during follow-up was estimated and compared by Cox proportional hazard regression model. The participants with metformin were first compared with all the parti-cipants who did not use metformin, and then were further compared with those who did not use hypoglycemic agents and those who used other hypoglycemic agents.
RESULTS:The patients with type 2 diabetes were with an average age of (59.5±8.7) years, and 41.9% of them were male. The median follow-up time was 4.5 years. A total of 84 patients developed ischemic stroke during follow-up, with a crude incidence of 6.4 (95%CI: 5.0-7.7) per 1 000 person-years. Among all the participants, 1 149 (43.8%) took metformin, 1 476 (56.2%) were metformin non-users, including 593 (22.6%) used other hypoglycemic agents, and 883 (33.6%) did not use any hypoglycemic agents. Compared with metformin non-users, the Hazard ratio (HR) for ischemic stroke in metformin users was 0.58 (95%CI: 0.36-0.93; P = 0.024). Compared with other hypoglycemic agents, HR was 0.48 (95%CI: 0.28-0.84; P < 0.01); Compared with the group without hypoglycemic agents, HR was 0.65 (95%CI: 0.37-1.13; P=0.13). The association between metformin and ischemic stroke was statistically significant in the patients ≥ 60 years old compared with all the metformin non-users and those who used other hypoglycemic agents (HR: 0.48, 95%CI: 0.25-0.92; P < 0.05). Metformin use was associated with a lower incidence of ischemic stroke in the patients with good glycemic control (0.32, 95%CI: 0.13-0.77; P < 0.05). In the patients with poor glycemic control, and the association was not statistically significant (HR: 0.97, 95%CI: 0.53-1.79; P>0.05). There was an interaction between glycemic control and metformin use on incidence of ischemic stroke (Pinteraction < 0.05). The results of the sensitivity analysis were consistent with the results in the main analysis.
CONCLUSION:Among patients with type 2 diabetic in rural areas of northern China, metformin use was associated with lower incidence of ischemic stroke, especially in patients older than 60 years. There was an interaction between glycemic control and metformin use in the incidence of ischemic stroke.
